Drugs.com - Clinical Trials

Zentalis Pharmaceuticals Presents Updated Azenosertib Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer...

Mar 18, 2025 - 01:11
 0
Zentalis Pharmaceuticals Presents Updated Azenosertib Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
SAN DIEGO, March 15, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer...
Read More

Tags:

Previous Article

Longévité : l'industrie cosmétique doit repenser son rapport à l'âge

Next Article

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Produ...

Related Posts

Emalex Biosciences’ Lead Candidate Meets Primary and Secondary Endpoints in Phase 3 Tourette Syndrome Study

Emalex Biosciences’ Lead Candidate Meets Primary and Se...

Mar 1, 2025  0

BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program

BioRestorative Receives FDA Fast Track Designation for ...

Mar 1, 2025  0

Boehringer’s Nerandomilast Meets Primary Endpoint in Phase III Study FIBRONEER™-ILD, in Progressive Pulmonary Fibrosis

Boehringer’s Nerandomilast Meets Primary Endpoint in Ph...

Feb 10, 2025  0